Following publication of the original article [1], the authors reported that the original version of this article unfortunately contained mistakes.

Page 1, section “Abstract”, the originally published texts were: Despite low bioavailability (0.024%), N-hydap exhibited a higher distribution in the lungs (26.26%), accounting for its efficacy against SCLC.

The correct texts should read: With a favorable bioavailability of 24.0%, N-hydap exhibited a higher distribution in the lungs (26.26%), accounting for its efficacy against SCLC.

Page 2, the presentation of Graphical Abstract “Low bioavailability (0.024%)” was incorrect.

The originally published Graphical Abstract was:

The corrected detail is Bioavailability (24.0%) and the corrected Graphical Abstract is shown below:

Page 7, section “2.4 Pharmacokinetic and distribution studies of N‑hydap”, second paragraph, the originally published texts were: Additionally, after oral administration, Cmax and AUC(0−t) showed a decrease, while CL exhibited an increase, indicating a faster elimination of N-hydap compared to tail vein injection, resulting in an oral bioavailability of only 0.024%.

The corrected texts should read: Additionally, after oral administration, Cmax and AUC(0−t) showed a decrease, while CL exhibited an increase, indicating a faster elimination of N-hydap compared to tail vein injection, resulting in an oral bioavailability of 24.0%.

Page 11, the presentation of Table 2 was incorrect.

The originally published Table 2 was:

Table 2 Pharmacokinetic parameters of N-hydap after oral administration (5 mg/kg) and tail vein injection (2 mg/kg) in mice (mean ± SD, n = 5)

The corrected Table 2 is given below:

Table 2 Pharmacokinetic parameters of N-hydap after oral administration (5 mg/kg) and tail vein injection (2 mg/kg) in mice (mean ± SD, n = 5)

Page 11, section “Discussion”, first paragraph, the original texts were: In our study, we found that the low oral bioavailability may indeed be associated with poor absorption.

The corrected texts should read: In our study, we found that the oral bioavailability may indeed be associated with absorption.

Page 11, section “Discussion”, first paragraph, the originally published texts were: For N-hydap given via gavage (5 mg/kg) and tail vein administration (2 mg/kg), the AUC(0 − t) values were 37.738 ± 10.352 μg/L * min and 62,912.962 ± 3214.586 μg/L * min, respectively. The calculated bioavailability was found to be 0.024%, indicating that the low bioavailability of N-hydap is indeed caused by poor absorption.

The corrected texts should read: For N-hydap given via gavage (5 mg/kg) and tail vein administration (2 mg/kg), the AUC(0−t) values were 84764.772 ± 23252.634 vs 141310.757 ± 7220.381 nM * min, respectively. The calculated bioavailability was found to be 24.0%.

Page 11, section “Discussion”, second paragraph, the originally published texts were: the original texts were: We believe the low bioavailability after gavage (0.024%) may be plausibly explained by the metabolic profile of N-hydap that it was rapidly eliminated during both CYP- and UGT-mediated reactions, which is consistent with the concept of the first-pass effect.

The corrected texts should read: We believe the bioavailability after gavage (24.0%) may be plausibly explained by the metabolic profile of N-hydap that it was rapidly eliminated during both CYP- and UGT-mediated reactions, which is consistent with the concept of the first-pass effect.

Page 11, section “Discussion”, second paragraph, the originally published texts were: Based on these findings, we conclude that the high rate of N-hydap conversion to N-hydap-G resulted in the extremely low oral bioavailability of N-hydap.

The corrected texts should read: Based on these findings, we conclude that the high rate of N-hydap conversion to N-hydap-G, first-pass elimination, resulted in an oral bioavailability of 24.0% for N-hydap.

Page 11, section “Discussion”, third paragraph, the originally published texts were: This finding suggests that although N-hydap has low bioavailability, it possesses strong activity against lung cancer.

The corrected texts should read: This finding suggests that N-hydap not only has favorable oral bioavailability, but also demonstrates notable accumulation targeting the lungs, possessing strong activity against lung cancer.

Page 11, section “Discussion”, fourth paragraph, the originally published texts were: Despite its low oral bioavailability, N-hydap exhibited potent pharmacological activity against lung cancer and N-hydap was highly safe. Therefore, if N-hydap is increased in oral bioavailability, it will be a good candidate for anti-SCLC.

The corrected texts should read: With favorable oral bioavailability, N-hydap exhibited potent pharmacological activity against lung cancer and it was highly safe. Therefore, if N-hydap is further increased in oral bioavailability, it will be a good candidate for anti-SCLC.

Page 15, section “Conclusion”, the originally published texts were: The findings revealed that N-hydap had an extremely low oral bioavailability due to its rapid metabolism by UGT enzymes, with UGT1A3 being the most significant contributor.

The corrected texts should read: The findings revealed that N-hydap had an oral bioavailability of 24.0% due to its rapid metabolism by UGT enzymes, with UGT1A3 being the most significant contributor.

Page 16, the content “0.024%” of the fifth row, fifth column of the Table 4 was incorrect. The corrected content is 24.0%.

The original article [1] has been updated.